Hospital-acquired pneumonia due to Achromobacter xylosoxidans in the elderly: A single-center retrospective study in Beijing

Journal of Infection in Developing Countries

Volumn 11, Issue 1, 2017, Pages 10-18

  Liu, Chao ^a   Guo, Jun ^b   Yan, Weifeng ^a   Jin, Yi ^a   Pan, Fei ^c   Fang, Xiangqun ^c   Qin, Long ^a   Liu, Changting ^c  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b TSINGHUA UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Achromobacter xylosoxidans; Elderly patients; Hospital acquired pneumonia; Imipenem; Resistance

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AZTREONAM; CARBAPENEM; CEFEPIME; CEFOPERAZONE PLUS SULBACTAM; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; GLUCOCORTICOID; IMIPENEM; IMMUNOSUPPRESSIVE AGENT; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METRONIDAZOLE; MINOCYCLINE; MOXIFLOXACIN; NITROFURANTOIN; NITROIMIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; PROTON PUMP INHIBITOR; QUINOLONE; SULFAMERAZINE PLUS TRIMETHOPRIM; TETRACYCLINE; VORICONAZOLE; ANTIINFECTIVE AGENT;

ACHROMOBACTER XYLOSOXIDANS; AGED; ANTIBIOTIC SENSITIVITY; APACHE; ARTICLE; CASE CONTROL STUDY; CATHETERIZATION; CHINA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL PULMONARY INFECTION SCORE; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; RESPIRATORY TRACT DISEASE ASSESSMENT; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; VERY ELDERLY; ACHROMOBACTER DENITRIFICANS; ANTIBIOTIC RESISTANCE; CROSS INFECTION; GENERAL HOSPITAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; INDWELLING CATHETER; ISOLATION AND PURIFICATION; MICROBIOLOGY; PATHOLOGY; PNEUMONIA, BACTERIAL; PUBLIC HOSPITAL;

ACHROMOBACTER DENITRIFICANS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BEIJING; BETA-LACTAM RESISTANCE; CATHETERS, INDWELLING; CROSS INFECTION; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITALS, GENERAL; HOSPITALS, VETERANS; HUMANS; IMIPENEM; MALE; PNEUMONIA, BACTERIAL; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 85011103239     PISSN: 20366590     EISSN: 19722680     Source Type: Journal    
DOI: 10.3855/jidc.8747     Document Type: Article

References (30)

1. Yabuuchi E, Oyama A (1971) Achromobacter xylosoxidans n. sp. from human ear discharge. Jpn J Microbiol 15: 477-481.
2. Tena D, Gonzalez-Praetorius A, Perez-Balsalobre M, Sancho O, Bisquert J (2008) Urinary tract infection due to Achromobacter xylosoxidans: report of 9 cases. Scand J Infect Dis 40: 84-87.
3. Knippschild M, Schmid EN, Uppenkamp M, König E, Meusers P, Brittinger G, Höffkes HG (1996) Infection by Alcaligenes xylosoxidans subsp. xylosoxidans in neutropenic patients. Oncology 53: 258-262.
4. Tena D, Carranza R, Barbera JR, Valdezate S, Garrancho JM, Arranz M, Saez-Nieto JA (2005) Outbreak of long-term intravascular catheter-related bacteremia due to Achromobacter xylosoxidans subspecies xylosoxidans in a hemodialysis unit. Eur J Clin Microbiol Infect Dis 24: 727-732.
5. Weitkamp J H, Tang Y W, Haas DW, Midha NK, Crowe JE Jr (2000) Recurrent Achromobacter xylosoxidans bacteremia associated with persistent lymph node infection in a patient with hyper-immunoglobulin M syndrome.pdf. Clin Infect Dis 31: 1183-1187.
6. Ramos JM, Fernández-Roblas R, García-Ruiz P, Soriano F (1995) Meningitis caused by Alcaligenes (Achromobacter) xylosoxidans associated with epidural catheter. Infection 23: 395-396.
7. Espinoza-Gómez F, Newton-Sánchez OA, Melnikov V, Virgen-González O, Unrau J (2007) Meningitis caused by Alcaligenes xylosoxidans in a patient with HIV AIDS. Braz J Infect Dis 11: 603-604.
8. Manckoundia P, Mazen E, Saloff Coste A, Somana S, Marilier S, Duez JM, Camus A, Popitean L, Bador J, Pfitzenmeyer P (2011) A case of meningitis due to Achromobacter xylosoxidans denitrificans 60 years after a cranial trauma. Med Sci Monit 17: CS63-CS65.
9. Gelfand MS, Cleveland KO (2014) Successful treatment with doripenem of ventriculitis due to Achromobacter xylosoxidans. QJM 107: 923-925.
10. Yamamoto M, Nagao M, Hotta G, Matsumura Y, Matsushima A, Ito Y, Takakura S, Ichiyama S (2012) Molecular characterization of IMP-type metallo-beta-lactamases among multidrug-resistant Achromobacter xylosoxidans. J Antimicrob Chemother 67: 2110-2113.
11. Rotstein C, Evans G, Born A, Grossman R, Light RB, Magder S, McTaggart B, Weiss K, Zhanel GG (2008) Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults. Can J Infect Dis Med Microbiol 19: 19-53.
12. Trancassini M, Iebba V, Citera N, Tuccio V, Magni A, Varesi P, De Biase RV, Totino V, Santangelo F, Gagliardi A, Schippa S (2014) Outbreak of Achromobacter xylosoxidans in an Italian Cystic fibrosis center: genome variability, biofilm production, antibiotic resistance, and motility in isolated strains. Front Microbiol 5: 138.
13. Tena D, Martinez NM, Losa C, Solis S (2014) Skin and soft tissue infection caused by Achromobacter xylosoxidans: report of 14 cases. Scand J Infect Dis 46: 130-135.
14. Clinical and Laboratory Standards Institute (2010) Performance standards for antimicrobial susceptibility testing:20th informational supplement. CLSI document M100-S20. Wayne, PA: CLSI.
15. Firdous S (2012) Concomitant tuberculous meningitis and Lutembacher syndrome with multiple atrial septal defects and infective. J Coll Physicians Surg Pak 22: 666-668.
16. Lipsky BA (2004) Medical treatment of diabetic foot infections. Clin Infect Dis 39Suppl 2:104-114.
17. Laheij RJF, Van Ijzendoorn MC, Janssen MJR, Jansen JBMJ (2003) Gastric acid-suppressive therapy and community-acquired respiratory infections. Aliment Pharmacol Ther 18: 847-851.
18. Ni W, Cai X, Liang B, Cai Y, Cui J, Wang R (2014) Effect of proton pump inhibitors on in vitro activity of tigecycline against several common clinical pathogens. PLoS One 9: e86715.
19. Xia J, Zhang D, Xu Y, Gong M, Zhou Y, Fang X (2014) A retrospective analysis of carbapenem-resistant Acinetobacter baumannii-mediated nosocomial pneumonia and the in vitro therapeutic benefit of cefoperazone/sulbactam. Int J Infect Dis 23: 90-93.
20. Aisenberg G, Rolston KV, Safdar A (2004) Bacteremia caused by Achromobacter and Alcaligenes species in 46 patients with cancer (1989-2003). Cancer 101: 2134-2140.
21. Gomez-Cerezo J, Suarez I, Rios JJ, Pena P, Garcia de Miguel MJ, de Jose M, Monteagudo O, Linares P, Barbado-Cano A, Vazquez JJ (2003) Achromobacter xylosoxidans bacteremia: a 10-year analysis of 54 cases. Eur J Clin Microbiol Infect Dis 22: 360-363.
22. Gahrn-Hansen B, Alstrup P, Dessau R, Fuursted K, Knudsen A, Olsen H, Oxhøj H, Petersen AR, Siboni A, Siboni K. (1988) Outbreak of infection with Achromobacter xylosoxidans from contaminated intravascular pressure transducers. J Hosp Infect 12: 1-6.
23. Vu-Thien H, Darbord JC, Moissenet D, Dulot C, Dufourcq JB, Marsol P, Garbarg-Chenon A (1998) Investigation of an outbreak of wound infections due to Alcaligenes xylosoxidanstransmitted by chlorhexidine in a burns unit. Eur J Clin Microbiol Infect Dis 17: 724-726.
24. Amoureux L, Bador J, Siebor E, Taillefumier N, Fanton A, Neuwirth C (2013) Epidemiology and resistance of Achromobacter xylosoxidans from cystic fibrosis patients in Dijon, Burgundy: first French data. J Cyst Fibros 12: 170-176.
25. Duggan J, Goldstein S, Chenoweth C, Kauffman C, Bradley S (1996) Achromobacter xylosoxidans bacteremia report of four cases and review of the literature. Clin Infect Dis 23: 569-576.
26. Saiman L, Chen Y, Gabriel PS, Knirsch C (2002) Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 46: 1105-1107.
27. VIM-2-containing class 1 integron. Diagn Microbiol Infect Dis 53: 215-220.
28. VIM-1)-containing integron carrying a new aminoglycoside phosphotransferase gene cassette. Antimicrob Agents Chemother 45: 1249-1253.
29. Sofianou D, Markogiannakis A, Metzidie E, Pournaras S, Tsakris A (2005) VIM-2 metallo-beta-lactamase in Achromobacter xylosoxidans in Europe. Eur J Clin Microbiol Infect Dis 24: 854-855.
30. Wang M, Ridderberg W, Hansen CR, Hoiby N, Jensen-Fangel S, Olesen HV, Skov M, Lemming LE, Pressler T, Johansen HK, Norskov-Lauritsen N (2013) Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis. J Cyst Fibros 12: 638-643.